sotalol has been researched along with Embryopathies in 17 studies
Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This was a retrospective study of patients treated for fetal tachycardia with sotalol in a pediatric cardiology department over a ten-year period." | 7.73 | Sotalol in the treatment of fetal tachyarrhythmia. ( Kaku, S; Macedo, AJ; Nogueira, G; Rebelo, M; Trigo, C, 2006) |
| "The aim of this study was to investigate the pharmacokinetics and pharmacodynamics of sotalol in the treatment of fetal tachycardia." | 7.72 | Treatment of fetal tachycardia with sotalol: transplacental pharmacokinetics and pharmacodynamics. ( Ambachtsheer, EB; Meijboom, EJ; Oudijk, MA; Ruskamp, JM; Stoutenbeek, P; Ververs, FF; Visser, GH, 2003) |
| "If the fetal atrial flutter is resistant to these therapies, a combination of other congenital cardiac diseases or organic abnormalities should be considered." | 5.33 | Fetal atrial flutter: a case report and experience of sotalol treatment. ( Chiu, TH; Ho, M; Huang, LC; Hung, YC; Lee, CC; Wu, TH, 2006) |
| "We performed a systematic review and meta-analysis to compare digoxin, flecainide, or sotalol as first-line therapy for fetal tachycardia." | 4.95 | Transplacental treatment of fetal tachycardia: A systematic review and meta-analysis. ( Frommelt, MA; Hill, GD; Kovach, JR; Saudek, DE; Singh, AK; Wehrheim, K, 2017) |
| " In the case of atrial flutters the pregnant woman is treated with sotalol administered orally and, if no sinus rhythm is obtained nor a reduced ventricular rhythm occurs, subsequently with digoxin." | 4.81 | [Protocols for the treatment of supraventricular tachycardias in the fetus]. ( Ambachtsheer, EB; Meijboom, EJ; Oudijk, MA; Stoutenbeek, P, 2001) |
| "This was a retrospective study of patients treated for fetal tachycardia with sotalol in a pediatric cardiology department over a ten-year period." | 3.73 | Sotalol in the treatment of fetal tachyarrhythmia. ( Kaku, S; Macedo, AJ; Nogueira, G; Rebelo, M; Trigo, C, 2006) |
| "The aim of this study was to investigate the pharmacokinetics and pharmacodynamics of sotalol in the treatment of fetal tachycardia." | 3.72 | Treatment of fetal tachycardia with sotalol: transplacental pharmacokinetics and pharmacodynamics. ( Ambachtsheer, EB; Meijboom, EJ; Oudijk, MA; Ruskamp, JM; Stoutenbeek, P; Ververs, FF; Visser, GH, 2003) |
| "The authors report two cases of fetal tachycardia treated in utero by digitalis (Digoxin) and a beta-blocker (Sotalol)." | 3.67 | [In utero treatment of fetal tachycardias with a digitalis-beta blocker combination. Apropos of 2 cases]. ( Auzelle, MP; Badoual, J; Boccara, JF; Caldera, R; Chavinie, J; Lachassine, E; Mensire, A, 1987) |
| "Standardized treatment of fetal tachyarrhythmia has not been established." | 2.90 | Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias: Multicenter Trial. ( Hagiwara, A; Hamasaki, T; Horigome, H; Ikeda, T; Inamura, N; Kato, H; Katsuragi, S; Kawataki, M; Maeno, Y; Miyoshi, T; Nii, M; Sago, H; Sakaguchi, H; Shimizu, W; Shiraishi, I; Taketazu, M; Ueda, K; Yamamoto, H; Yasukochi, S; Yoda, H, 2019) |
| "Fetal hydrops was seen in 20 patients; 17 received maternal therapy, 2 were delivered and 1 was not treated because it had a severe nontreatable cardiac malformation." | 2.69 | Atrial flutter in the perinatal age group: diagnosis, management and outcome. ( Benatar, AA; Brenner, JI; Kleinman, CS; Lisowski, LA; Meijboom, EJ; Soyeur, DJ; Stoutenbeek, P; Verheijen, PM, 2000) |
| "Fetal hydrops was present in six patients (five with SVT, one with AF)." | 1.39 | Sotalol as first-line treatment for fetal tachycardia and neonatal follow-up. ( Freund, MW; Manten, GT; Oudijk, MA; Pistorius, L; ter Heide, H; van der Heijden, LB, 2013) |
| "Flecainide and digoxin were superior to sotalol in converting SVT to a normal rhythm and in slowing both AF and SVT to better-tolerated ventricular rates and therefore might be considered first to treat significant fetal tachyarrhythmia." | 1.37 | Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study. ( Api, O; Blom, NA; Carvalho, JS; Clur, SA; De Groot, E; Jaeggi, ET; Manlhiot, C; McCrindle, BW; Rammeloo, L; Ryan, G, 2011) |
| "If the fetal atrial flutter is resistant to these therapies, a combination of other congenital cardiac diseases or organic abnormalities should be considered." | 1.33 | Fetal atrial flutter: a case report and experience of sotalol treatment. ( Chiu, TH; Ho, M; Huang, LC; Hung, YC; Lee, CC; Wu, TH, 2006) |
| "Sotalol was given orally to the mothers in a dose of 80-160 mg x 2." | 1.30 | Foetal supraventricular tachycardia treated with sotalol. ( Fouron, JC; Jaeggi, E; Sonesson, SE; Wesslen-Eriksson, E; Winberg, P, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 7 (41.18) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Miyoshi, T | 2 |
| Maeno, Y | 2 |
| Hamasaki, T | 2 |
| Inamura, N | 2 |
| Yasukochi, S | 2 |
| Kawataki, M | 2 |
| Horigome, H | 2 |
| Yoda, H | 2 |
| Taketazu, M | 2 |
| Nii, M | 2 |
| Hagiwara, A | 2 |
| Kato, H | 2 |
| Shimizu, W | 2 |
| Shiraishi, I | 2 |
| Sakaguchi, H | 2 |
| Ueda, K | 2 |
| Katsuragi, S | 2 |
| Yamamoto, H | 2 |
| Sago, H | 2 |
| Ikeda, T | 2 |
| Refaat, M | 1 |
| El Dick, J | 1 |
| Sabra, M | 1 |
| Bitar, F | 1 |
| Tayeh, C | 1 |
| Abutaqa, M | 1 |
| Arabi, M | 1 |
| Hill, GD | 1 |
| Kovach, JR | 1 |
| Saudek, DE | 1 |
| Singh, AK | 1 |
| Wehrheim, K | 1 |
| Frommelt, MA | 1 |
| Shozu, M | 1 |
| Strasburger, JF | 1 |
| Cuneo, BF | 1 |
| Jaeggi, ET | 1 |
| Carvalho, JS | 1 |
| De Groot, E | 1 |
| Api, O | 1 |
| Clur, SA | 1 |
| Rammeloo, L | 1 |
| McCrindle, BW | 1 |
| Ryan, G | 1 |
| Manlhiot, C | 1 |
| Blom, NA | 1 |
| Shah, A | 1 |
| Moon-Grady, A | 1 |
| Bhogal, N | 1 |
| Collins, KK | 1 |
| Tacy, T | 1 |
| Brook, M | 1 |
| Hornberger, LK | 1 |
| van der Heijden, LB | 1 |
| Oudijk, MA | 3 |
| Manten, GT | 1 |
| ter Heide, H | 1 |
| Pistorius, L | 1 |
| Freund, MW | 1 |
| Jouannic, JM | 1 |
| Delahaye, S | 1 |
| Le Bidois, J | 1 |
| Fermont, L | 1 |
| Villain, E | 1 |
| Dommergues, M | 1 |
| Dumez, Y | 1 |
| Ruskamp, JM | 1 |
| Ververs, FF | 1 |
| Ambachtsheer, EB | 2 |
| Stoutenbeek, P | 3 |
| Visser, GH | 1 |
| Meijboom, EJ | 3 |
| Rebelo, M | 1 |
| Macedo, AJ | 1 |
| Nogueira, G | 1 |
| Trigo, C | 1 |
| Kaku, S | 1 |
| Wu, TH | 1 |
| Huang, LC | 1 |
| Ho, M | 1 |
| Lee, CC | 1 |
| Chiu, TH | 1 |
| Hung, YC | 1 |
| Sonesson, SE | 1 |
| Fouron, JC | 1 |
| Wesslen-Eriksson, E | 1 |
| Jaeggi, E | 1 |
| Winberg, P | 1 |
| Lisowski, LA | 1 |
| Verheijen, PM | 1 |
| Benatar, AA | 1 |
| Soyeur, DJ | 1 |
| Brenner, JI | 1 |
| Kleinman, CS | 1 |
| Auzelle, MP | 1 |
| Mensire, A | 1 |
| Lachassine, E | 1 |
| Caldera, R | 1 |
| Boccara, JF | 1 |
| Chavinie, J | 1 |
| Badoual, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety Assessment for Sotalol Protocol in Outpatient Unit[NCT05418036] | Phase 4 | 110 participants (Anticipated) | Interventional | 2020-10-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for sotalol and Embryopathies
| Article | Year |
|---|---|
Sotalol as an effective adjunct therapy in the management of supraventricular tachycardia induced fetal hydrops fetalis.
Topics: Adult; Anti-Arrhythmia Agents; Digoxin; Drug Therapy, Combination; Female; Fetal Diseases; Flecainid | 2020 |
Transplacental treatment of fetal tachycardia: A systematic review and meta-analysis.
Topics: Anti-Arrhythmia Agents; Digoxin; Female; Fetal Diseases; Fetal Therapies; Flecainide; Humans; Pregna | 2017 |
[Protocols for the treatment of supraventricular tachycardias in the fetus].
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Clinical Protocols; Digoxin; Drug Therapy, Combination; Fema | 2001 |
2 trials available for sotalol and Embryopathies
| Article | Year |
|---|---|
Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias: Multicenter Trial.
Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Atrial Flutter; Cesarean Section; Digoxin; Fema | 2019 |
Atrial flutter in the perinatal age group: diagnosis, management and outcome.
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Digoxin; Echocardiography, Doppler; Electric Countershock; E | 2000 |
12 other studies available for sotalol and Embryopathies
| Article | Year |
|---|---|
Antenatal antiarrhythmic treatment for fetal tachyarrhythmias: a study protocol for a prospective multicentre trial.
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Child Development; Child, Preschool; Digoxin; Drug Therapy, | 2017 |
Re: Sotalol as first-line treatment for fetal tachycardia and neonatal follow-up. L. B. van der Heijden, M. A. Oudijk, G. Manten, H. ter Heide, L. Pistorius and M. W. Freund. Ultrasound Obstet Gynecol 2013; 42: 285-293.
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Female; Fetal Diseases; Humans; Pregnancy; Sotalol; Tachycar | 2013 |
Treatment of fetal tachycardia.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiac Electrophysiology; Digoxin; Female; Fetal Diseases; Huma | 2008 |
Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study.
Topics: Anti-Arrhythmia Agents; Digoxin; Drug Evaluation; Female; Fetal Diseases; Fetal Therapies; Flecainid | 2011 |
Effectiveness of sotalol as first-line therapy for fetal supraventricular tachyarrhythmias.
Topics: Abortion, Induced; Anti-Arrhythmia Agents; Atrial Flutter; Bradycardia; Catheter Ablation; Digoxin; | 2012 |
Sotalol as first-line treatment for fetal tachycardia and neonatal follow-up.
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Echocardiography; Female; Fetal Diseases; Follow-Up Studies; | 2013 |
[Results of prenatal management of fetuses with supraventricular tachycardia. A series of 66 cases].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Clinical Protocols; Digoxin; Echocardiography; F | 2003 |
Treatment of fetal tachycardia with sotalol: transplacental pharmacokinetics and pharmacodynamics.
Topics: Amniotic Fluid; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Female; Fetal Blood; Fetal | 2003 |
Sotalol in the treatment of fetal tachyarrhythmia.
Topics: Anti-Arrhythmia Agents; Fetal Diseases; Humans; Retrospective Studies; Sotalol; Tachycardia | 2006 |
Fetal atrial flutter: a case report and experience of sotalol treatment.
Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Delivery, | 2006 |
Foetal supraventricular tachycardia treated with sotalol.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Female; Fetal Diseases; Gestational Age; Humans | 1998 |
[In utero treatment of fetal tachycardias with a digitalis-beta blocker combination. Apropos of 2 cases].
Topics: Digoxin; Drug Therapy, Combination; Electrocardiography; Female; Fetal Diseases; Humans; Pregnancy; | 1987 |